$16,800
List price
$12,500
Planned net
25.6%
Gross-to-net erosion
1 of 6
Levers that durably work
Contents
1. The Most Misunderstood Number in Commercial Planning
The product will be priced at $16,800 a year. The business case is built on $12,500 a year. The difference — 25.6% — is gross-to-net erosion, and almost everyone outside commercial underestimates it.
| Value | |
|---|---|
| List price (WAC), per patient-year | $16,800 |
| Planned net price | $12,500 |
| Planned gross-to-net erosion | 25.6% |
| Largest single deduction | Commercial rebates — $2,520, 15% of list |
| Governance status | ⚠ The assumption behind these figures has not been refreshed since the original case — the recorded basis of the CFO's abstention at Gate 4 |
Roughly a quarter of the headline price never reaches the company, and the largest part of that
buys access rather than volume.
This is the distinction that makes pharmaceutical pricing unlike almost any other. A rebate is not a volume discount. It is a payment for formulary position — for being one of the products a plan will cover on preferred terms. The plan does not commit to buying more; it commits to not making it hard for physicians to prescribe.
Which means the money is spent before a single additional unit moves, and it is spent against a competitor's rebate rather than against a demand curve.
This is the distinction that makes pharmaceutical pricing unlike almost any other. A rebate is not a volume discount. It is a payment for formulary position — for being one of the products a plan will cover on preferred terms. The plan does not commit to buying more; it commits to not making it hard for physicians to prescribe.
Which means the money is spent before a single additional unit moves, and it is spent against a competitor's rebate rather than against a demand curve.
2. The Waterfall
| Step | Per patient-year | % of WAC | Running | What it is |
|---|---|---|---|---|
| List price (WAC) | $16,800 | — | $16,800 | What the product is priced at. Almost nobody pays it. |
| Commercial rebates | $-2,520 | 15.0% | $14,280 | Paid to pharmacy benefit managers for formulary position. The largest single deduction, and it buys access rather than volume. |
| Medicaid and 340B statutory discounts | $-1,010 | 6.0% | $13,270 | Set by statute, not negotiated. Scales with the share of volume in those channels. |
| Copay assistance | $-520 | 3.1% | $12,750 | Paid by the manufacturer to reduce patient out-of-pocket cost. Rises when coverage is poor — it is the mechanism that partly offsets a weak access position, at the manufacturer's expense. |
| Distribution and channel fees | $-250 | 1.5% | $12,500 | Wholesaler and specialty pharmacy fees. |
| Net price per patient-year | $12,500 | 25.6% gross-to-net erosion. This is the number the business case uses. |
Every line below the first is a deduction the company agrees to, and only one of them is
negotiable at the moment of decision.
Medicaid and 340B discounts are set by statute and scale with channel mix — they are a consequence of who the patients are, not of anything commercial decides. Distribution fees are contractual and small. Copay assistance is demand-driven, and §4 explains why that makes it dangerous.
The rebate is the only line where a decision is genuinely being made, and it is the largest line by a wide margin. The strategy in this document is almost entirely a strategy about that one number.
Medicaid and 340B discounts are set by statute and scale with channel mix — they are a consequence of who the patients are, not of anything commercial decides. Distribution fees are contractual and small. Copay assistance is demand-driven, and §4 explains why that makes it dangerous.
The rebate is the only line where a decision is genuinely being made, and it is the largest line by a wide margin. The strategy in this document is almost entirely a strategy about that one number.
3. Pricing Into a Class, Not a Vacuum
| Product | List price | Formulary position | What it means for us |
|---|---|---|---|
| Incumbent A | $15,900 | Preferred on 2 of 3 national formularies | ⚠ Entrenched. Its rebate is already priced into every plan's economics, and displacing it costs more than matching it. |
| Incumbent B | $16,400 | Preferred on 1 of 3, non-preferred elsewhere | The realistic displacement target rather than Incumbent A. |
| Competitor C (filing ~18 months ahead) | unknown | Not yet approved | ⚠ Will set its price before ours is fixed. A fourth entrant prices into a market three others have already defined. |
A fourth entrant does not set a price. It responds to three that already exist.
Incumbents A and B have list prices, established rebate levels and formulary positions that plans have already built their economics around. Competitor C will file roughly eighteen months ahead of us and will set its price before ours is fixed — so this program will be pricing into a market whose structure is fully determined by others.
The realistic target is Incumbent B, which holds preferred position on one of three national formularies rather than two. Displacing Incumbent A would cost more in rebate than the incremental position is worth, and a plan that has been contracted with A for years has switching costs of its own.
Incumbents A and B have list prices, established rebate levels and formulary positions that plans have already built their economics around. Competitor C will file roughly eighteen months ahead of us and will set its price before ours is fixed — so this program will be pricing into a market whose structure is fully determined by others.
The realistic target is Incumbent B, which holds preferred position on one of three national formularies rather than two. Displacing Incumbent A would cost more in rebate than the incremental position is worth, and a plan that has been contracted with A for years has switching costs of its own.
4. What Actually Moves Net Price
| Lever | Does it work? | Why |
|---|---|---|
| Raise list price | Negative | ⚠ Raises the rebate a plan demands roughly in step, so net barely moves — and it raises patient out-of-pocket, which raises copay assistance. List price is close to irrelevant; net price is everything. |
| Deepen the rebate | Real, and one-way | Buys formulary position. ⚠ It cannot be withdrawn later without losing the position it bought, so every concession sets a floor. |
| Hold price, accept non-preferred tier | Real | Protects net per unit and reduces volume. Viable only if the product has a claim that drives demand through prior authorization. |
| Increase copay assistance | Negative at the margin | ⚠⚠ Rises automatically when coverage is poor. It partly offsets weak access at the manufacturer's expense, so a bad access position makes each remaining unit more expensive to sell. |
| Differentiating clinical claim | Real, and the only durable one | ⚠ Changes the rebate a plan can demand rather than the price offered. Not available to this program unless the tolerability endpoint clears the hierarchy. |
| Launch timing into the formulary cycle | Real | Missing a cycle costs a year of preferred-tier opportunity and cannot be bought back with price. |
Two of the six levers make things worse, and one of them operates automatically.
Raising list price is close to pointless: the rebate a plan demands rises roughly in step, so net barely moves, while patient out-of-pocket rises and drags copay assistance up with it. List price is nearly irrelevant; net price is everything, and a company that manages its list price is managing a number that mostly affects its own deduction line.
Copay assistance is worse, because it rises on its own when coverage is poor. A patient facing a high out-of-pocket cost under a non-preferred tier needs more assistance to stay on therapy — so a weak access position does not merely reduce volume. ⚠ It makes each remaining unit more expensive to sell. The two effects compound rather than offset.
Raising list price is close to pointless: the rebate a plan demands rises roughly in step, so net barely moves, while patient out-of-pocket rises and drags copay assistance up with it. List price is nearly irrelevant; net price is everything, and a company that manages its list price is managing a number that mostly affects its own deduction line.
Copay assistance is worse, because it rises on its own when coverage is poor. A patient facing a high out-of-pocket cost under a non-preferred tier needs more assistance to stay on therapy — so a weak access position does not merely reduce volume. ⚠ It makes each remaining unit more expensive to sell. The two effects compound rather than offset.
The only durable lever is the one this program may not have. A differentiating clinical claim changes the rebate a plan can demand, rather than the price the company offers — it shifts the negotiation instead of conceding within it. That is why the tolerability claim is worth more than any pricing decision in this document, and why its position fourth in the testing hierarchy is a commercial fact rather than a statistical one.
5. The Decisions
| Decision | Status | Reasoning |
|---|---|---|
| Parity pricing to Incumbent B | Recommended | Price at approximate parity rather than at a discount. ⚠ A discount without a differentiating claim signals weakness and sets a floor the product never recovers from. |
| Rebate ceiling fixed before negotiation | Recommended | A walk-away point agreed with the Committee in advance. Negotiating without one means conceding until somebody senior notices. |
| No launch-price discount to buy volume | Recommended | Volume bought with price is volume that cannot later be repriced. The class has no precedent for recovering a launch concession. |
| Plan for non-preferred tier at launch | ⚠ Required by the calendar | The formulary cycle closes before approval. The launch operating model must assume exception-based access, not placement. |
Price at parity, not at a discount — and this is the recommendation most likely to be
challenged.
The instinct for a fourth entrant is to buy share with price. It fails for a specific reason: a discount without a differentiating claim signals weakness rather than value. A plan offered a cheaper equivalent does not conclude the product is better value; it concludes the manufacturer knows it has nothing else to offer, and it prices every subsequent negotiation from there.
A price concession without a differentiating claim sets a floor the product never recovers from. In this class there is no precedent for recovering a launch concession — the rebate that bought position in year one becomes the baseline for year two.
The instinct for a fourth entrant is to buy share with price. It fails for a specific reason: a discount without a differentiating claim signals weakness rather than value. A plan offered a cheaper equivalent does not conclude the product is better value; it concludes the manufacturer knows it has nothing else to offer, and it prices every subsequent negotiation from there.
A price concession without a differentiating claim sets a floor the product never recovers from. In this class there is no precedent for recovering a launch concession — the rebate that bought position in year one becomes the baseline for year two.
The rebate ceiling matters as much as the opening price. A walk-away point agreed with the Committee before negotiation begins is the only protection against conceding incrementally until somebody senior notices — and negotiations conducted against a formulary deadline are exactly where that happens.
6. Why the Assumption Was Never Refreshed
The 25.6% erosion figure has stood since the original business case. It is the single most consequential un-updated number in the program, and the reason is worth stating.
| Why it was not refreshed | Assessment |
|---|---|
| Nobody owned it after the case was written | ⚠ It sat inside the business case rather than in a register with an owner and a review date. Numbers inside documents do not get reviewed; entries in registers do. |
| Refreshing it required payer input the program had not gathered | The advisory board program that would produce it began in 2026 and is behind. The evidence needed to update the assumption is the same evidence that is late. |
| It was not obviously wrong | 26% was defensible when written. ⚠ An assumption does not announce that it has aged — it simply stops being tested against a market that has moved. |
| The person who noticed had no mechanism except abstention | The CFO could not compel a refresh, and voting against a program he believed should proceed would have been overruled. The abstention was the only instrument available. |
The mechanism that failed here is not analytical. It is that a load-bearing assumption lived
inside a document instead of inside a register.
Every register in this program — risks, issues, decisions, dependencies, gate conditions — has an owner, a review cadence and a place where it is read aloud. The gross-to-net assumption had none of those, because it was a number in a business case, and business cases are written once.
The transferable fix is small and cheap: put load-bearing assumptions in the assumptions register with an owner and an expiry date, so that "this has not been checked in eighteen months" becomes a reportable fact rather than something a CFO has to notice.
Every register in this program — risks, issues, decisions, dependencies, gate conditions — has an owner, a review cadence and a place where it is read aloud. The gross-to-net assumption had none of those, because it was a number in a business case, and business cases are written once.
The transferable fix is small and cheap: put load-bearing assumptions in the assumptions register with an owner and an expiry date, so that "this has not been checked in eighteen months" becomes a reportable fact rather than something a CFO has to notice.
Assumption A-04 now carries it, with an owner and a review date. That is a correction made two years late, and it is recorded here rather than in the closure report because the program can still act on it — the refresh is achievable before Gate 5 if the outstanding advisory boards are completed.